Impact of Fusion of Indium-111 Capromab Pendetide Volume Data Sets with Those from MRI or CT in Patients with Recurrent Prostate Cancer

Schettino, C. J.; Kramer, Elissa L.; Noz, Marilyn E.; Taneja, Samir S.; Padmanabhan, Priya; Lepor, Herbert

doi:10.2214/ajr.183.2.1830519

Cited by 66 publications

(39 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yet, diagnostic performance in the subsequent literature varied widely, with sensitivities of 17%-92% and specifi cities of 47%-86%-likely refl ecting differences in intraobserver variability and study population and design ( 9,11-14, 27,28 ). Fusion with CT or MR images has been reported to improve accuracy ( 24,26,29 ). In our study, the sensitivity of 111…”

Section: Nuclear Medicine: Detection Of Recurrent Prostate Carcinomamentioning

confidence: 61%

See 1 more Smart Citation

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

Schuster

Savir-Baruch²,

Nieh³

et al. 2011

Radiology

139

130

View full text Add to dashboard Cite

Purpose:To compare the diagnostic performance of the synthetic amino acid analog radiotracer anti -1-amino-3-fl uorine 18-fl uorocyclobutane-1-carboxylic acid ( anti -3-18 F-FACBC) with that of indium 111 ( 111 In)-capromab pendetide in the detection of recurrent prostate carcinoma. Materials andMethods:This prospective study was approved by the institutional review board and complied with HIPAA guidelines. Written informed consent was obtained. In-capromab pendetide single photon emission computed tomography (SPECT)/CT were performed within 6 weeks of each other. Studies were evaluated by two experienced interpreters for abnormal uptake suspicious for recurrent disease in the prostate bed and extraprostatic locations. The reference standard was a combination of tissue correlation , imaging, laboratory, and clinical data. Diagnostic performance measures were calculated and tests of the statistical signifi cance of differences determined by using the McNemar x 2 test as well as approximate tests based on the difference between two proportions. Results:For disease detection in the prostate bed, anti -3-18 F-FACBC had a sensitivity of 89 % (32 of 36 patients; 95% confi dence interval [CI]: 74%, 97%), specifi city of 67% (eight of 12 patients; 95% CI: 35%, 90%), and accuracy of 83% (40 of 48 patients; 95% CI: 70%, 93%).111 In-capromab pendetide had a sensitivity of 69% (25 of 36 patients; 95% CI: 52%, 84%), specifi city of 58% (seven of 12 patients; 95% CI: 28%, 85%), and accuracy of 67% (32 of 48 patients; 95% CI: 52%, 80%). In the detection of extraprostatic recurrence, anti -3-18 F-FACBC had a sensitivity of 100% (10 of 10 patients; 95% CI: 69%, 100%), specifi city of 100% (seven of seven patients; 95% CI: 59%, 100%), and accuracy of 100% (17 of 17 patients; 95% CI: 80%, 100%).111 In-capromab pendetide had a sensitivity of 10% (one of 10 patients; 95% CI: 0%, 45%), specifi city of 100% (seven of seven patients; 95% CI: 59%, 100%), and accuracy of 47% (eight of 17 patients; 95% CI: 23%, 72%). Conclusion:anti -3-18 F-FACBC PET/CT was more sensitive than 111 Incapromab pendetide SPECT/CT in the detection of recurrent prostate carcinoma and is highly accurate in the differentiation of prostatic from extraprostatic disease.

show abstract

Section: Nuclear Medicine: Detection Of Recurrent Prostate Carcinomamentioning

confidence: 61%

“…Uptake was considered to be abnormal when there was activity or asymmetries of increased uptake compared to background expected biodistribution in normal adjacent organs or structures (22)(23)(24).…”

mentioning

confidence: 99%

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

Schuster

Savir-Baruch²,

Nieh³

et al. 2011

Radiology

139

130

View full text Add to dashboard Cite

show abstract

“…34 -36 Fusion of multiple imaging modalities such as Indium-111 Capromab Pendetide volume data sets withMRI and CT appears to improve the accuracy in assessing potential sites for salvage radiotherapy in patients with progression after radical prostatectomy (Table 1). 35 Future studies should help determine whether incorporating these or other imaging modalities will improve our ability to cure prostate cancer and/or reduce the morbidity of our treatment.…”

Section: Advances In Radiation Therapymentioning

confidence: 99%

“…In addition, pretreatment port films do not allow corrections to be made to account for organ movement. Modified from Schettino J, Kramer EL, Noz ME, et al 35 CA …”

Section: Accurately Defining the Prostate And Intraprostatic Diseasementioning

confidence: 99%

Advances in Radiation Therapy: Conventional to 3D, to IMRT, to 4D, and Beyond

Bucci

Bevan

Roach

2005

CA: A Cancer Journal for Clinicians

292

182

View full text Add to dashboard Cite

Modern advances in computers have fueled parallel advances in imaging technologies. The improvements in imaging have in turn allowed a higher level of complexity to be incorporated into radiotherapy treatment planning systems. As a result of these changes, the delivery of radiotherapy evolved from therapy designed based primarily on plain (two dimensional) x-ray images and hand calculations to three-dimensional x-ray based images incorporating increasingly complex computer algorithms. More recently, biologic variables based on differences between tumor metabolism, tumor antigens, and normal tissues have been incorporated into the treatment process. In addition, greater awareness of the challenges to the accuracy of the treatment planning process, such as problems with set-error and organ movement, have begun to be systematically addressed, ushering in an era of so-called FourDimensional Radiotherapy. This review article discusses how these advances have changed the way the most common neoplasms are treated now and will be treated in the near future. (CA Cancer J Clin 2005;55:117-134.)

show abstract

“…Single photon emission computerized tomography with indium-111 capromab pendetide (Prostascint) is undergoing further refinements, such as fusion with CT or MRI, 24,25 which may improve its utility in detecting extraprostatic tumor involvement.…”

Section: Preoperative Assessmentmentioning

confidence: 99%

Salvage HIFU for recurrent prostate cancer after radiotherapy

Chalasani

Martínez

Lim

et al. 2008

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Recurrent disease following primary radiotherapy for localized prostate cancer is a common problem, occurring in up to 46% of patients. For these patients, therapeutic options include salvage prostatectomy, salvage cryotherapy, salvage high-intensity focused ultrasound (HIFU), hormonal therapy or observation. This review will focus on the emerging evidence for salvage HIFU. There are no randomized or prospective studies in this area. Efficacy results of 17-57% have been reported from retrospective case series, with reported toxicity including rectal fistula in 0-16%, and incontinence in 10-50%. The ideal patient, while yet to be clearly defined, should have preradiotherapy low or intermediate risk disease. Salvage HIFU appears most appropriate for those patients with histologically proven local recurrence only, with a life expectancy of at least 5 years and with some medical comorbidities rendering them not ideal for salvage prostatectomy.

show abstract

Impact of Fusion of Indium-111 Capromab Pendetide Volume Data Sets with Those from MRI or CT in Patients with Recurrent Prostate Cancer

Abstract: Although Prosta-Scint SPECT alone can help in the proper management of recurrent prostate cancer, fusion with MRI-CT of the pelvis can improve the specificity of the examination.

Cited by 66 publications

References 27 publications

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

Advances in Radiation Therapy: Conventional to 3D, to IMRT, to 4D, and Beyond

Salvage HIFU for recurrent prostate cancer after radiotherapy

Contact Info

Product

Resources

About

Impact of Fusion of Indium-111 Capromab Pendetide Volume Data Sets with Those from MRI or CT in Patients with Recurrent Prostate Cancer

Abstract: Although Prosta-Scint SPECT alone can help in the proper management of recurrent prostate cancer, fusion with MRI-CT of the pelvis can improve the specificity of the examination.

Cited by 66 publications

References 27 publications

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-18F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and111In–Capromab Pendetide SPECT/CT

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-18F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and111In–Capromab Pendetide SPECT/CT

Advances in Radiation Therapy: Conventional to 3D, to IMRT, to 4D, and Beyond

Salvage HIFU for recurrent prostate cancer after radiotherapy

Contact Info

Product

Resources

About

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT